A source-linked monthly briefing of practice-relevant approvals, safety alerts, guideline releases, and major evidence. Updated through September 1, 2026.
6 pathway steps
Your learning progress0 of 31 chapters complete
Saved privately in this browser and shared across state tabs.
Didactics
Shared across all locations
Fresh evidence is not automatically clinical policy. This chapter is a briefing layer. A monthly evidence agent searches, source-checks, publishes the briefing, and links every item to its primary source.
Six-month briefing: March 2–September 1, 2026
This rolling edition prioritizes developments most likely to affect an APP’s clinic, counseling, coordination, medication reconciliation, or pathway knowledge. “APP takeaway” means what to notice or coordinate—not authority to independently initiate a new oncology regimen.
13 reviewed updatesAs of 2026-09-01 · window starts 2026-03-02
Source-checked evidence briefing. Publishing an item here does not change a clinical pathway; the monthly agent is prohibited from editing core clinical content.
Prostate cancerRandomized phase 3 trial
Dose-escalated radiotherapy improves long-term progression-free survival in high-risk prostate cancer
What changed
In GETUG AFU 18, 505 men with high-risk prostate cancer at 25 French centers received long-term androgen-deprivation therapy plus either 80 Gy or 70 Gy conventionally fractionated prostate radiotherapy. At 9.5 years median follow-up, 10-year progression-free survival was 83.6% with 80 Gy versus 72.2% with 70 Gy (HR 0.56), while grade 3 or worse late toxicity was similar at 8% versus 7%.
Why it matters
The phase 3 result strengthens the case for adequate radiation dose in high-risk localized disease and gives APPs concrete long-term data for referral coordination and treatment counseling.
APP takeaway
Make sure high-risk patients reach radiation oncology for an individualized dose and fractionation discussion; do not translate this result directly to modern hypofractionated or SBRT schedules. The trial was open-label, used conventional fractionation with long-term ADT, did not establish a prostate-cancer-specific or overall-survival benefit, and reported 10-year progression-free survival post hoc because event counts were low. It was funded by the French National Cancer Institute and AstraZeneca, and several authors reported outside industry relationships.
Rezūm outperformed combination BPH medication for symptoms at 1 year
What changed
VAPEUR randomized 151 sexually active men with symptomatic benign prostatic obstruction to Rezūm water-vapor thermal therapy or an alpha blocker plus a 5-alpha-reductase inhibitor. At 1 year, mean IPSS improvement was 10.8 versus 6.2 points (between-group difference -4.6), and quality-of-life improvement favored Rezūm.
Why it matters
This is direct randomized evidence comparing a common minimally invasive BPH procedure with combination medication rather than with a sham or another procedure.
APP takeaway
Use the result to support a balanced medication-versus-procedure discussion, not an automatic pathway change. Superiority for preserving sexual function was not demonstrated, treatment-related adverse events were more frequent with Rezūm (40% versus 28%), serious adverse events were 12% versus 1.3%, and follow-up is currently limited to 1 year. The trial was conducted in selected sexually active men, and several coauthors were Boston Scientific employees.
Suzetrigine supports an opioid-sparing multimodal strategy
What changed
A recent phase 4 study evaluated suzetrigine (Journavx) with acetaminophen and ibuprofen after selected laparoscopic and arthroscopic procedures. Among 46 evaluable participants, 76.1% did not use opioid rescue and 90.9% rated pain control good, very good, or excellent.
Why it matters
A first-in-class non-opioid NaV1.8 pain-signal inhibitor could help urology build effective acute-pain pathways that avoid routine opioids after procedures and during other moderate-to-severe acute pain episodes.
APP takeaway
Consider suzetrigine within an approved multimodal acute-pain protocol and current labeling, not as a stand-alone replacement for evaluation or source control. This was a small, nonrandomized study; several authors were Vertex employees and the procedures were not urologic, so urology-specific outcomes still need study.
Pluvicto moves into PSMA-positive metastatic hormone-sensitive disease
What changed
FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) with androgen-receptor pathway inhibitor therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Why it matters
Radioligand therapy is no longer confined to later metastatic castration-resistant settings for appropriately selected PSMA-positive patients.
APP takeaway
Flag eligible metastatic hormone-sensitive patients for PSMA-PET–based oncology review; do not alter therapy without the treating oncology team and current prescribing information.
AUA confirms multiple 2026 guideline releases and amendments
What changed
AUA’s official published-guideline list identifies 2026 editions for benign prostatic hyperplasia, surgical management of kidney stones, and vasectomy, plus a 2026 amendment to advanced prostate cancer.
Why it matters
These releases map directly to several high-use chapters in this guide.
APP takeaway
This entry is link-only because AUA restricts third-party AI reuse of its guideline content. A designated clinician should review the licensed source and document any approved pathway changes manually.
Perioperative pembrolizumab plus enfortumab vedotin expands to all cystectomy candidates with MIBC
What changed
FDA approved pembrolizumab, including its subcutaneous formulation, with enfortumab vedotin as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer.
Why it matters
The indication expanded from cisplatin-ineligible patients to all patients with MIBC who are candidates for cystectomy.
APP takeaway
Expect perioperative systemic-therapy discussions earlier in the cystectomy pathway and verify the oncology plan, adverse-effect monitoring, and timing around surgery.
Anticoagulation and urinary bleedingMeta-analysis of randomized trials
Left-atrial-appendage occlusion may matter when anticoagulation sustains recurrent hematuria
What changed
A 2026 Bayesian meta-analysis of six randomized trials (7,004 participants) found less nonprocedural clinically relevant bleeding with left-atrial-appendage occlusion than oral anticoagulation (pooled RR 0.59), but no clear evidence of clinically meaningful noninferiority for stroke prevention and no similar reduction in major bleeding.
Why it matters
For a patient with nonvalvular atrial fibrillation and recurrent clinically important urinary bleeding while anticoagulated, reducing long-term anticoagulant exposure may be a high-impact cross-specialty strategy when urologic treatment alone has not solved the problem.
APP takeaway
After completing the urologic bleeding evaluation and treating reversible causes—including BPH-directed options such as PAE when appropriate—consider cardiology or electrophysiology referral to assess candidacy for left-atrial-appendage occlusion. WATCHMAN treats atrial-fibrillation stroke risk, not BPH or hematuria; it is not appropriate for every anticoagulated patient, and postimplant antithrombotic therapy still requires coordination.
First oral carbapenem approved for complicated UTI
What changed
FDA approved tebipenem pivoxil (Utebzi) tablets for adults with complicated UTI, including pyelonephritis, caused by susceptible organisms when patients have limited or no alternative oral options.
Why it matters
This creates an oral option in a setting that may otherwise require intravenous carbapenem therapy, but the indication is deliberately restricted.
APP takeaway
Use only with culture and susceptibility data, antimicrobial-stewardship review, and the current label; it is not a routine substitute for standard oral UTI therapy.
PTEN testing becomes actionable in metastatic hormone-sensitive prostate cancer
What changed
FDA approved capivasertib with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, together with an FDA-authorized companion diagnostic.
Why it matters
A biomarker-defined treatment option now enters the metastatic hormone-sensitive setting.
APP takeaway
Confirm PTEN testing and oncology ownership; anticipate monitoring for hyperglycemia, diarrhea, cutaneous reactions, and the usual abiraterone-related issues using current prescribing information.
Belzutifan plus pembrolizumab enters adjuvant clear-cell RCC
What changed
FDA approved belzutifan with pembrolizumab after nephrectomy for adults with clear-cell RCC at intermediate-high or high recurrence risk, including selected patients rendered no-evidence-of-disease after metastasectomy.
Why it matters
Adjuvant therapy now includes a new combination rather than pembrolizumab alone for an eligible high-risk population.
APP takeaway
Make sure postoperative pathology and recurrence-risk classification reach oncology; monitor for anemia and hypoxia with belzutifan and immune-mediated toxicity with pembrolizumab.
Orlistat labeling adds kidney-stone and kidney-injury warnings
What changed
FDA approved label changes for OTC alli (orlistat) warning about kidney stones and rare acute kidney injury, aligning kidney-risk language across approved orlistat products.
Why it matters
Patients may obtain the drug without a prescription and may not volunteer its use during a stone or kidney-injury evaluation.
APP takeaway
Add OTC weight-loss products to medication reconciliation in stone formers and patients with unexplained flank pain, hematuria, oliguria, or acute kidney injury.
Durvalumab plus BCG approved for BCG-naïve high-risk NMIBC
What changed
FDA approved durvalumab with BCG induction and maintenance for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer.
Why it matters
Systemic immunotherapy now enters the initial BCG-based treatment pathway for a defined high-risk NMIBC population.
APP takeaway
Confirm that the patient is BCG-naïve and high risk, coordinate intravesical and systemic schedules, and reinforce immune-related adverse-event education.
ctDNA molecular residual disease becomes treatment-selecting after cystectomy
What changed
FDA approved atezolizumab formulations as adjuvant treatment after cystectomy for adults with MIBC who have ctDNA molecular residual disease detected by an FDA-authorized test; Signatera CDx was approved as the companion diagnostic.
Why it matters
Serial molecular residual-disease testing can now directly select an adjuvant treatment rather than serving only as prognostic information.
APP takeaway
Verify postoperative ctDNA testing and results, ensure positive patients reach oncology promptly, and track serial testing during the recommended window when results remain negative.
Monthly: the evidence agent searches official FDA sources, focused PubMed evidence, major guidelines, and relevant adjacent specialties.
Wide relevance filter: the scan includes core urology plus pain control, anticoagulation and bleeding, cardiology devices, obesity medicine, oncology, infectious disease, imaging, and perioperative care when the downstream urologic impact is clear.
Source check: every item must resolve to an authoritative primary source. Press releases and unsupported claims are rejected.
Agent briefing: the agent writes “what changed,” “why it matters,” and the APP takeaway, identifies affected chapters, and labels limitations or conflicts that materially affect interpretation.
Automatic publication: after the build and acceptance checks pass, the agent commits the updated briefing to GitHub and Railway deploys it.
Core-pathway firewall: the monthly agent may edit only Chapter 30 and its update data. It cannot alter another chapter, a clinical pathway, dosing, or local policy.
Source policy
Automatically researched: FDA sources, PubMed citation and abstract data, guideline-release pages, trial registries, and relevant cross-specialty evidence.
Automatically source-checked: the agent must open the cited source, distinguish regulatory action from emerging evidence, and state important study limitations.
AUA: link-only monitoring. AUA restricts third-party AI reuse of its guideline content, so the automation does not scrape, copy, or summarize it.
No press-release medicine: manufacturer announcements are not published as practice updates unless confirmed in an authoritative primary source.
Clinical Pathway
Click any node to expand
The monthly evidence agent protects the guide from both staleness and hype: it researches and source-checks an APP-facing briefing, publishes it only after the site passes every check, and is prohibited from rewriting an existing clinical pathway.
Automatic discovery, source verification, transparent publication, and a firewall around clinical policy.
Select a box to open its teaching details.
Automatic sources
FDA What's New: Drugs RSS
FDA MedWatch Safety Alerts RSS
Focused PubMed E-utilities searches for major urology trials, guidelines, and meta-analyses
Pain, anticoagulation, cardiology devices, obesity medicine, oncology, infection, imaging, and perioperative evidence relevant to urology
Not automatically ingested
AUA guideline text because of its third-party AI-use restrictions
Manufacturer press releases without confirmation from an authoritative primary source
Ch 30 — source policy
The collector keeps
Urology-related FDA items
Recent randomized trials, practice guidelines, and meta-analyses from focused PubMed queries
Source title, date, URL or PMID, and topic
The collector removes
Items already published
Items already pending review
Items outside the configured lookback window
Ch 30 — weekly automation
What every item contains
Title and date
Primary-source link
Source type and topic
What changed, why it matters, and a bounded APP takeaway
Important limitations or conflicts when they affect interpretation
Safety guardrail
The agent may summarize evidence for Chapter 30, but it may not alter dosing, another chapter, a pathway, or local policy.
Ch 30 — review request
Required verification
What changed
Why it matters
APP takeaway
Evidence or regulatory type
Affected chapters
Source URL resolves and publication date is within the reporting window
Study design, population, limitations, and conflicts are not overstated
Agent decision
Publish
Hold for more evidence
Reject as irrelevant or unreliable
Ch 30 — clinical review
Publication gate
Date, topic, and evidence label
What changed and why it matters
APP takeaway
Affected chapters
Direct primary-source link
Content validation, full site build, 218-page acceptance audit, and clean diff
Ch 30 — published update card
Time-critical
To change an existing pathway
Confirm applicability to US practice and local policy
Review current labeling, formulary, privileges, and operational capability
Make a separate explicit chapter/pathway edit
Run the complete acceptance checks
Record the clinical approver
The rule
Fresh does not automatically mean practice-changing.